Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Ustekinumab May Be Effective for Lupus

Lara C. Pullen, PhD  |  November 12, 2018

New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupussystemic lupus erythematosus (SLE)ustekinumab

8 Ways to Help Your Patients with Medication Costs

Vanessa Caceres  |  October 18, 2018

A patient with rheumatoid arthritis (RA) comes to your office and needs a medication. You prescribe it, and the patient’s insurance plan covers it. The patient begins the medication and slowly but surely feels better. Prescribing drugs for a patient should be this simple but rarely is, thanks to the high cost of drugs and…

Filed under:Drug UpdatesPatient PerspectivePractice Support Tagged with:cost savingdrug costs

Fighting Lupus Among Latinas

From the College  |  October 18, 2018

Systemic lupus erythematosus (SLE) is more prevalent among Hispanic women than white women, according to two recent studies published in Arthritis & Rheumatology.1,2 However, Latinas often lack awareness of lupus, which can contribute to delays in diagnosis and treatment, and lead to worse outcomes. “One of the challenges is reaching out to the Latino community,…

Filed under:Education & TrainingFrom the CollegeSystemic Lupus Erythematosus Tagged with:Collaboration InitiativesCollaborative Initiatives Special Committee (COIN)

Permanent Vision Loss in Late Giant Cell Arteritis

Kimberly Retzlaff  |  October 18, 2018

Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

Filed under:ConditionsVasculitis Tagged with:peripheral arthritisPolymyalgia Rheumaticavision lossvisual loss

Study Suggests Tocilizumab Monotherapy May Work for Some RA Patients

Mary Beth Nierengarten  |  October 18, 2018

For patients with rheumatoid arthritis (RA) who respond to subcutaneous tocilizumab, discontinuing methotrexate may be an option and offer an alternative to patients who cannot tolerate or prefer not to take methotrexate. “This is one of the first studies showing that methotrexate may be discontinued in a cohort of patients with a biologic agent without…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Methotrexatetocilizumab

Palindromic Rheumatism: Will It Progress to Severe Rheumatoid Arthritis?

Amaka Odonwodo, MD, MPH, & Carlos Julio Aponte, MD, FACP, FACR  |  October 18, 2018

Palindromic rheumatism (PR) was first described in 1944 as “unique in its nature of recurrent, transient episodes of excruciatingly painful inflammation of articular and periarticular tissues, followed by periods without symptoms.”1 Unfortunately, it is becoming evident this entity is more frequent than we thought.2 PR is easily ignored or misdiagnosed due to its character (i.e.,…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Classification CriteriaPalindromic Rheumatism

Nivolumab-Induced Arthritis

Catherine Strahle, DO, Nathalie E. Chalhoub, MD, & Avis Ware, MD  |  October 18, 2018

Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Cancercase reportimmune checkpoint inhibitor (ICI)nivolumabPsoriatic Arthritisskin psoriasis

Lupus Patient Develops Miller Fisher Variant of Guillain-Barré Syndrome

Sedrick Bradley, MD, & Nirupa J. Patel, MD  |  October 18, 2018

Systemic lupus erythematosus (SLE) is a heterogeneous, auto­immune, inflammatory, connective tissue disease affecting multiple organs. Neither central nervous system nor peripheral nervous systems are spared. The neurologic system is involved in a wide range of 10–80% of patients with SLE. Peripheral neuropathy, such as Guillain-Barré syndrome (GBS) and its variants, can occur in neurologic complications…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:areflexiaataxiaGuillain-Barré SyndromeMiller Fisher Syndromeophthalmoplegia

An Overview of Pediatric, Noninfectious Uveitis

Joseph McDonald, MD, Virginia Miraldi Utz, MD, & Sheila T. Angeles-Han, MD, MS  |  October 18, 2018

Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Juvenile Arthritis (JIA)Uveitis

Genes, Not Diet, Main Determinant of Urate Levels

Anne Harding  |  October 17, 2018

NEW YORK (Reuters Health)—Heredity plays a substantially larger role than diet in determining serum urate levels, according to new findings in BMJ. Nearly 25% of the variation in serum urate is attributable to common genetic variants, while dietary pattern explained less than 1%, Dr. Tanya J. Major of the University of Otago in Dunedin, New…

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Goutheredityserum urate levelsTanya J. Major

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 70
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences